

For Immediate Release

January 15, 2024

Contact: Ron Lattanze, rlattanze@lucernodynamics.com

Lucerno Dynamics and Carilion Clinic Announce Radiotherapy Administration Milestone

Carilion Clinic's molecular imaging team is the first to use the innovative Lara® Real-Time Visualization technology to help ensure the highest level of safety in the administration of radiotherapeutics.

Cary, NC – Lucerno Dynamics, a North Carolina-based medical technology company, today announced the worldwide first use of Lara® Real-Time Visualization (RTV) in a clinical setting at Carilion Roanoke Memorial Hospital, Carilion Clinic's flagship facility.

"Carilion Clinic is the worldwide leader in the safe administration of radiopharmaceuticals," said Ron Lattanze, CEO of Lucerno Dynamics. "The Carilion team continues to demonstrate their commitment to ensuring patients are monitored for the safe administration of radioactive drugs. Carilion is the first nuclear medicine center in the world to actively monitor radiotherapy administrations using our latest product, Lara® RTV."

Lara® RTV ensures the highest level of quality for therapeutic and diagnostic radiopharmaceutical administrations. It is designed to provide early insight on the quality of radiopharmaceutical therapy deliveries used in cancer care. This gives clinical teams the ability to stop a poor administration, minimizing unintended radiation exposure, while maximizing the benefits therapies provide.

"The latest Lara® System is an ideal solution for high-dose radiopharmaceutical administrations," said Jackson Kiser, M.D., Medical Director of Molecular Imaging for Carilion. "It helps our clinicians monitor and ensure the accurate and complete delivery of the radiopharmaceutical. It also offers our patients confidence, knowing that these critical and expensive treatments are being administered with the highest level of precision and care."

In addition to providing real-time counts on the Lara reader's LCD screen, Lara® RTV creates a real-time graphical view of the administration on a computer monitor. Clinicians can see the time-activity curve as it develops from the beginning of the administration and throughout the uptake period.

"I welcome additional tools as well as methods to monitor, analyze and optimize radiopharmaceutical administrations," said Jason Mace, Senior Diagnostic Physicist and Radiation Safety Officer at Carilion. "We're committed to improving patient care and excited about the future of radiopharmaceutical therapy and future innovation."

For further information on the Lara® RTV, please visit <https://lucerno.com/lara-rtv/>